Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial

ObjectivesThis study is designed in order to compare the efficacy and safety of recombinant human growth hormone (rhGH) with the reference brand.MethodsAccording to the inclusion criteria, 85 people in 13 Iranian centers were randomly selected to receive biosimilar Somatropin (Somatin (R)) (44 people) and reference Somatropin (Norditropin (R)) (41 people) at a dose of 35 mu g/kg/d, seven days/week for 12 months. The primary outcomes included height velocity (HV) was measured during 12 months of treatment.ResultsThe two intervention groups' Height changes were similar. The mean HV was 10.96 cm/year in the biosimilar group and 10.05 cm/year in the reference groups after 12 months. Estimates of the lower bounds of 95% CI for mean height differences in the biosimilar intervention group compared to the reference intervention group did not exceed the 2 cm margin. Therefore, the non-inferiority of biosimilar intervention compared to the brand product is verified. Common ADRs in both groups were nausea in two patients (2.4%), diarrhea in two patients (2.4%), increased body temperature in one patient (1.2%), and headache in one patient (1.2%).ConclusionsThe finding of this study indicated that Somatin (R) and Norditropin (R) have comparable efficacy and safety profiles.Clinical trial registrationwww.IRCT.irIRCT20171122037571N1.